)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Perspective Therapeutics
Perspective Therapeutics (CATX) investor relations material
Perspective Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
Cash, cash equivalents and short-term investments totaled $201.7M at September 30, 2026, and were expected to fund planned operations and clinical milestones into 2028.
VMT-α-NET and VMT01 updates showed interim clinical activity; PSV359 received FDA Fast Track Designation and gained a Merck collaboration for potential Keytruda combination evaluation.
Financial highlights
Q3 grant revenue was $20K vs. $209K YoY; operating expenses were $34.3M vs. $28.1M, operating loss was $34.3M vs. $27.9M, and net loss was $32.4M vs. $26.0M.
Q3 R&D expense was $26.1M vs. $20.3M and G&A expense was $8.3M vs. $7.7M; non-operating income, net, was $1.9M in both periods.
9M grant revenue was $177K vs. $841K; operating expenses were $92.0M vs. $74.6M and net loss was $85.4M vs. $65.6M. R&D expense rose to $69.0M from $51.3M, driven by staffing, trials, CMC and manufacturing work.
Outlook and guidance
Cash and short-term investments were expected to fund planned clinical milestones and operational investments into 2028; R&D and manufacturing costs are expected to rise.
An FDA End-of-Phase 2 meeting for VMT-α-NET is targeted for Q1 2027; PSV359 clinical data updates are planned for 2027.
VMT01 monotherapy patients enrolled since the cohort reopened in Q3 2026 are expected to reach at least 24 weeks of follow-up by mid-2027.
Chicago-area manufacturing site construction is expected to finish in early 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Perspective Therapeutics
- VMT-α-NET showed 50% ORR at 6.0 mCi and 71.9% PFS at 18 months.CATX
Study update - VMT-α-NET showed up to 50% ORR with no Grade 4 or 5 TEAEs.CATXMorgan Stanley 24th Annual Global Healthcare Conference
- Cash of $236.9M supports clinical expansion as net loss widens with R&D and manufacturing growth.CATXQ2 2026
- Alpha emitter therapy shows high efficacy and safety in NETs, with phase III readiness advancing.CATXRBC Capital Markets Global Healthcare Conference 2026
- VMT-α-NET demonstrates high response rates as pivotal trial planning and manufacturing expansion progress.CATXBank of America Global Healthcare Conference 2026
- Net loss increased to $26.2M as R&D ramped up, with cash rising to $271M after equity raise.CATXQ1 2026
- Director elections, auditor ratification, and annual say-on-pay vote set for May 2026.CATXProxy filing
- 44% response rate and durable disease control in SSTR2+ NETs with strong safety profile.CATXStudy Update
- Lead-212 platform advances with expanding manufacturing and promising early clinical results.CATXBarclays 27th Annual Global Healthcare Conference
Next Perspective Therapeutics earnings date
Q4 202625 Mar, 2027
Perspective Therapeutics
Next Perspective Therapeutics earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Perspective Therapeutics Inc (formerly Isoray, Inc.) is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are entering Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations. In 2023 Isoray, Inc., a medical technology company and innovator in seed brachytherapy, completed its merger with privately-held Viewpoint Molecular Targeting, Inc. The combined companies’ focus will be the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies so that precision, targeted medical doses are delivered directly to cancer patient tumor sites.